US equities |
SPCX $167.10 ▲+5.12% NVDA $236.44 ▲+1.06% MU $1,064.44 ▼-0.97% TSLA $378.60 ▲+2.16% MSFT $525.33 ▲+1.51% SNDK $1,708.71 ▼-0.66% INTC $117.38 ▼-1.64% META $744.71 ▲+2.28%
FinancialContent

Articles published by BiondVax Pharmaceuticals Ltd.

News headline image
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax Reports Second Quarter Financial Results and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax to Present at BIO-Europe Spring
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax Presenting at BIO CEO & Investor Conference
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax to Present at Biotech Showcase 2023
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax CEO Issues Letter to Shareholders
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax Announces Closing of $8 Million Underwritten Public Offering
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV
News headline image
BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Tickers BVXV